including cardiopulmonary and genitourinary complications, were all similar except a higher likelihood of returning back to operating room in the TKA group. (27.9% vs 12.4%; P < .01; Table I ) TKA was an independent risk factor for reoperation (hazard ratio, 2.71; confidence interval, 1.66-4.44; P < .01). However, postoperative mortality was not associated with TKA (P ¼ .77) or reoperation (P ¼ .42) but with patient physiologic conditions (dyspnea, sepsis, emergent operation, high American Society of Anesthesiologists score, and dependent lifestyle; Table II) .
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Management of Chronic Massive Traumatic Popliteal Artery Aneurysm: A Case Series With Evolution of Treatment
Ali Khalifeh, Rami Kantar, Bryan Buckingham, Samantha Cox, Robert Crawford, Rajabrata Sarkar, Shahab Toursavadkohi.
1 University of Maryland, Baltimore, Md
Objectives: Giant traumatic popliteal artery (PA) pseudoaneurysms (PSA) are rare but limb-threatening if untreated. Management can be challenging because no standardized approach exists. This report evaluates our experience with three patients treated differently.
Methods: A retrospective record review was performed after patients were identified by the surgeon.
Results: The first patient is a 58-year-old woman who presented with left popliteal swelling after total knee replacement complicated by infection requiring hardware removal and staged knee replacement. Ultrasound imaging showed a 10-Â 5-Â 5-cm PA-PSA. We performed an open exclusion of the PSA with contralateral reversed saphenous vein graft bypass. On annual follow-up, the graft was occluded; however, distal flow was preserved through collaterals (Fig 1) . The second patient is an 84-year-old woman who presented for a slowly enlarging left popliteal soft tissue mass. She reported a previous fall and hyperextension knee injury. Magnetic resonance imaging demonstrated a 10-Â 20-Â 10-cm PA-PSA. Local exploration, PSA excision, and small saphenous vein patch angioplasty were performed (Fig 2) . She remains without complications at 3 months of follow-up. The third patient is a 58-year-old man with The patient initially suffered from right lower extremity edema (A) that was evaluated with a venous duplex to rule out a deep vein thrombosis. B, A large popliteal artery pseudoaneurysm was identified while performing the venous duplex. C, After gaining endovascular access, a stent was successfully deployed in the popliteal artery, covering the neck and stopping the flow into the pseudoaneurysm. cirrhosis admitted for hepatic decompensation. A few weeks prior to admission, the patient was suffering from worsening hepatic encephalopathy causing multiple falls. Ultrasound evaluation of right lower extremity swelling for deep venous thrombosis showed a 9-cm PA-PSA. Treatment included endovascular coverage of PSA neck with stent graft and endovascular exclusion (Fig 3) . He remains without complications at 4 months of follow-up.
Conclusions: Traumatic chronic giant PA-PSA can be limb-or even lifethreatening if untreated. Treatment is individualized based on patient disease and comorbidities. Endovascular and local repair are safe alternatives to standard graft bypass.
Author Disclosures: B. Buckingham: Nothing to disclose; S. Cox: Nothing to disclose; R. Crawford: Nothing to disclose; R. Kantar: Nothing to disclose; A. Khalifeh: Nothing to disclose; R. Sarkar: Nothing to disclose; S. Toursavadkohi: Nothing to disclose.
IP213. Ethnic Minorities With Critical Limb Ischemia Derive Equal Amputation Risk Reduction From Autologous Cell Therapy Compared to Caucasians
S. Keisin Wang, Linden Green, Cliff Babbey, Michael Wilson, Raghu Motaganahalli, Andres Fajardo, Alok Gupta, Michael P. Murphy. Indiana University, Indianapolis, Indiana
Objectives: Ethnic minorities with critical limb ischemia (CLI) have historically done worse compared to Caucasians in regards to amputation risk reduction and amputation-free survival (AFS) after peripheral vascular interventions. This analysis was performed to determine whether this CLI precedent also extended to injections of concentrated bone marrow aspirate (cBMA) to the affected limb of patients without a revascularization option.
Methods: The treatment arm of the randomized, double-blind, multicenter MOBILE trial was stratified by ethnicity and evaluated for demographics, comorbidities, and outcomes. Primary end point was 1-year AFS (above-ankle or greater). Noninferiority analysis was performed with the margin set at a hazard ratio of 1.297.
Results: There were 37 non-Caucasian patients (9 placebo, 28 cBMA) with "no surgical option" CLI randomized to placebo or cBMA at a 1:3 ratio during the MOBILE trial. There was no difference in outcomes between the ethnic minority (African Americans, Hispanics, others) and the Caucasian population (Fig) . At the 1-year follow-up mark for the treatment group, overall AFS was 84%. Of the 28 minorities randomized to cBMA intervention, 25 (89%) survived amputation free compared to a rate of 82% in Caucasians, and 22 of 24 (92%) African Americans survived amputation free at 1-year follow-up. Noninferiority testing confirmed no difference in cBMA-treated patients by ethnicity when looking at amputation risk reduction; however, the null hypothesis could not be rejected when looking at AFS. No significant differences were noted when comparing cBMA treated patients by ethnicity in terms of quality of life, pain, ankle-brachial index, toebrachial index, transcutaneous pressure of oxygen, and 6-minute walk testing.
Conclusions: The MOBILE trial demonstrates noninferiority of cBMA intervention in minorities with "no option" CLI for amputation risk prevention. cBMA, therefore, represents a novel treatment option and should be aggressively explored for minorities who face impending amputation secondary to progressive, end-stage CLI.
Author Disclosures: C. Babbey: Nothing to disclose; A. Fajardo: Cook Medical: Contracted Research, Other Financial or Material Support; L. Green: Nothing to disclose; A. Gupta: Nothing to disclose; R. Motaganahalli: Nothing to disclose; M. P. Murphy: Nothing to disclose; S. Wang: Nothing to disclose; M. Wilson: Nothing to disclose.
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Midterm Results After Drug-Eluting Stenting of Superficial Femoral Artery in Critical Limb Ischemia: An Italian Multicenter Registry
Giuseppe Galzerano, Giulia Mazzitelli, Mariagnese Mele, Francesco Setacci, Gianmarco de Donato, Carlo Setacci. University of Siena, Tuscany, Italy
Objectives: On behalf of Zorro Collaborators. This is a preliminary report of an Italian Multicenter Registry "the ZORRO (ZilverÒ PTXÒ Observational Registry on Recanalization for Obstructive disease) trial." Aim of the study is to evaluate the effectiveness of the Zilver PTX in superficial femoral artery (SFA) treatment, in patients with critical limb ischemia (CLI).
Methods: All patients treated with the drug-eluting stent (Zilver PTX, Cook Medical) were enrolled from 12 different Italian vascular centers and prospectively included in a registry lasting from the October 1, 2013, to August 30, 2015. Inclusion criteria were patients with CLI (Rutherford >3) and reference vessel diameters of 4 to 9 mm. Multilevel disease, as iliac or tibial involvement and treatment, did not represent an exclusion criteria. Outcomes evaluated in this report were 12-month patency rate (PR) and amputation free survival rate (LS) and estimated 24-month PR and LS.
Results: Seventy-five patients were recorded in the registry. Forty-three patients presented TASC C and D lesions, 59 received a primary treatment, and 16 had previous endovascular or surgical treatment of the reference vessel. Median length of the lesion was 10.7 cm (range 1-33 cm). No patients were lost at follow-up. All patients reached 12 months of follow-up and 25 patients reached 24 months. PR and LS at 12 months of follow-up were 93.3% and 93.3%, respectively, and at 24 months of follow-up were 84.9% and 94.6%, respectively. Thirteen patients required reinterventions at 12 months; however we observed only three stent occlusions, and the treatment in two cases was addressed only to tibial vessels.
Conclusions: This preliminary data encourage wise use of the drugeluting stent in SFA for CLI treatment. Zilver PTX seems to provide durable and effective treatment for SFA. Longer follow-up data are needed to confirm these preliminary findings.
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